Clinical characteristics and outcomes of thymoma‐associated myasthenia gravis

Rodrigo Álvarez‐Velasco,Gerardo Gutiérrez‐Gutiérrez,Juan Carlos Trujillo,Elisabeth Martínez,Sonia Segovia,Marina Arribas‐Velasco,Guillermo Fernández,Carmen Paradas,Beatriz Vélez‐Gómez,Carlos Casasnovas,Velina Nedkova,Antonio Guerrero‐Sola,Alba Ramos‐Fransi,Alicia Martínez‐Piñeiro,Julio Pardo,Teresa Sevilla,María Teresa Gómez‐Caravaca,Adolfo López de Munain,Ivonne Jericó,Ana L. Pelayo‐Negro,María Asunción Martín,Yolanda Morgado,María Dolores Mendoza,Helena Pérez‐Pérez,Ricard Rojas‐García,Janina Turon‐Sans,Luis Querol,Eduard Gallardo,Isabel Illa,Elena Cortés‐Vicente
DOI: https://doi.org/10.1111/ene.14820
2021-03-30
European Journal of Neurology
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Prognosis of myasthenia gravis (MG) in patients with thymoma is not well established. Moreover, it is not clear whether thymoma recurrence or unresectable lesions entail a worse prognosis of MG.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>This multicenter study was based on data from a Spanish neurologist‐driven MG registry. All patients were &gt;18 years at onset and had anti‐acetylcholine receptor antibodies. We compared the clinical data of thymomatous and non‐thymomatous patients. Prognosis of patients with recurrent or non‐resectable thymomas was assessed.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>We included 964 patients from 15 hospitals: 148 (15.4%) had thymoma‐associated MG. Median follow‐up time was 4.6 years. At onset, thymoma‐associated MG patients were younger (52.0 vs 60.4, p&lt;0.001), had more generalized symptoms (OR: 3.02, 95%CI: 1.95‐4.68, p&lt;0.001) and more severe clinical forms according to MGFA scale (OR: 1.6, 95%CI: 1.15‐2.21, p=0.005). Disease severity based on the MGFA‐PIS scale was higher in thymomatous patients at 1 year, 5 years and end of follow‐up. Treatment refractoriness and mortality were also higher (OR: 2.28; 95%CI: 1.43‐3.63; p=0.001) (HR: 2.46; 95%CI: 1.47‐4.14; p=0.001). Myasthenic symptoms worsened in 13 of 27 patients with recurrences but differences in long‐term severity were not significant. Fifteen thymomatous patients had non‐resectable thymomas with worse MGFA‐PIS and higher mortality at the end of follow‐up.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Thymoma‐associated MG patients had more severe myasthenic symptoms and worse prognosis. Thymoma recurrence was frequently associated with transient worsening of MG but long‐term prognosis did not differ from non‐recurrent thymoma. Patients with non‐resectable thymoma tended to present severe forms of MG.</p></section>
neurosciences,clinical neurology
What problem does this paper attempt to address?